跳至主要内容
临床试验/NCT00242099
NCT00242099已完成4 期

The Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant: A Randomized Trial

University Health Network, Toronto2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2005年2月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
160
试验地点
2
主要终点
Adverse clinic events due to direct or indirect effects.

研究概览

简要总结

Human herpesvirus-6 (HHV-6) and -7 (HHV-7) infections are common after transplantation. Such infections may predispose transplant patients to other infections, contribute to a recurrence of hepatitis C virus, and affect rejection and function of the transplanted liver. Given the significant clinical impact of these viruses, routine laboratory monitoring may be beneficial by identifying patients who have persistent or high levels of infection. In these patients, immunosuppressive medications could be adjusted, or antiviral medications administered. There are currently no randomized trials that address this important question. This prospective, randomized trial will analyze whether routine laboratory monitoring for HHV-6 and -7 is clinically useful, and whether it would improve overall outcomes in transplant recipients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients who fulfill the following criteria are eligible for inclusion:
  • Recipients of a liver transplant
  • Able to give written informed consent
  • Are willing and able to comply with the protocol
  • Age >= 18 years

排除标准

  • The following patients are not eligible for inclusion in the study:
  • Patients unwilling or unable to give informed consent

结局指标

主要结局

Adverse clinic events due to direct or indirect effects.

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验